NYSEARCA:LCTX - NYSE Arca - US53566P1093 - Common Stock - Currency: USD
0.9844
+0.03 (+3.53%)
The current stock price of LCTX is 0.9844 USD. In the past month the price decreased by -4.43%. In the past year, price increased by 9.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.7 | 349.84B | ||
AMGN | AMGEN INC | 13.22 | 154.98B | ||
GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
INSM | INSMED INC | N/A | 20.78B | ||
NTRA | NATERA INC | N/A | 20.75B |
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
LINEAGE CELL THERAPEUTICS IN
2173 Salk Avenue, Suite 200
Carlsbad CALIFORNIA 92008 US
CEO: Brian M. Culley
Employees: 70
Phone: 15105213390
The current stock price of LCTX is 0.9844 USD. The price increased by 3.53% in the last trading session.
The exchange symbol of LINEAGE CELL THERAPEUTICS IN is LCTX and it is listed on the NYSE Arca exchange.
LCTX stock is listed on the NYSE Arca exchange.
13 analysts have analysed LCTX and the average price target is 4 USD. This implies a price increase of 305.83% is expected in the next year compared to the current price of 0.9844. Check the LINEAGE CELL THERAPEUTICS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LINEAGE CELL THERAPEUTICS IN (LCTX) has a market capitalization of 224.80M USD. This makes LCTX a Micro Cap stock.
LINEAGE CELL THERAPEUTICS IN (LCTX) currently has 70 employees.
LINEAGE CELL THERAPEUTICS IN (LCTX) has a support level at 0.94. Check the full technical report for a detailed analysis of LCTX support and resistance levels.
The Revenue of LINEAGE CELL THERAPEUTICS IN (LCTX) is expected to decline by -18.85% in the next year. Check the estimates tab for more information on the LCTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LCTX does not pay a dividend.
LINEAGE CELL THERAPEUTICS IN (LCTX) will report earnings on 2025-08-12, after the market close.
LINEAGE CELL THERAPEUTICS IN (LCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
The outstanding short interest for LINEAGE CELL THERAPEUTICS IN (LCTX) is 12.35% of its float. Check the ownership tab for more information on the LCTX short interest.
ChartMill assigns a technical rating of 7 / 10 to LCTX. When comparing the yearly performance of all stocks, LCTX is one of the better performing stocks in the market, outperforming 94.24% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to LCTX. LCTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LCTX reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 42.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.5% | ||
ROE | -20.51% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to LCTX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 9.9% and a revenue growth -18.85% for LCTX